{"classes":[{"categories":[{"measurements":[{"comment":"NA = Not Available. 75th percentile value not calculable due to insufficient data.","groupId":"OG000","lowerLimit":"10.6","upperLimit":"NA","value":"20.0"},{"groupId":"OG001","lowerLimit":"8.3","upperLimit":"24.7","value":"13.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"88"}],"units":"Participants"}],"description":"DoR was defined only for patients who had an objective response, as the time in days from date of first documentation of response (CR/PR) until date of disease progression. CR was disappearance of all target lesions since baseline; any pathological lymph nodes selected as TL to have a reduction in short axis to \\<10 mm. At least a 30% decrease in the sum of the diameters of TL, taking as reference the baseline sum of diameters.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Patients received fulvestrant (Faslodex™) 500 mg, administered as two 5 mL intramuscular injections, 1 in each buttock, at each visit on Days 0, 14 (±3), 28 (±3) and every 28 (±3) days thereafter. In order to support the double-blind, double-dummy design of the trial, each patient randomised to receive fulvestrant, also received placebo to match the anastrozole schedule (tablets, once daily).","id":"OG000","title":"Fulvestrant 500 mg"},{"description":"Patients received anastrozole (Arimidex™), administered orally as a single tablet at a dose of 1 mg/day from randomisation on Day 0 and once daily thereafter. In order to support the double-blind, double-dummy design of the trial, each patient randomised to receive anastrozole also received placebo to match the fulvestrant schedule (injections on Days 0, 14 \\[±3\\], 28 \\[±3\\] and every 28 \\[±3\\] days thereafter).","id":"OG001","title":"Anastrozole 1 mg"}],"paramType":"MEDIAN","populationDescription":"Only patients in the ITT analysis set (which included all randomised patients), who also had an objective response and had measurable disease at baseline were included in the DoR analysis (n=89 for Fulvestrant arm and n=88 for Anastrozole arm).","reportingStatus":"POSTED","timeFrame":"Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until disease progression or treatment discontinuation (up to approximately 38 months)","title":"Duration of Response (DoR) for Fulvestrant Treatment Versus Anastrozole Treatment","type":"SECONDARY","unitOfMeasure":"Months"}